Thalia Therapeutics

Default features description for sign up page.

Regulatory news

Home

Media

AIM Rule 26

Open Sans

THALIA THERAPEUTICS INVESTOR CENTRE

In the last episode, Nuvec: Revolutionising Drug Delivery, we explored how Nuvec® is designed to overcome the key challenges of RNA delivery, including protection, stability, and effective cell uptake. If you haven’t seen it yet, be sure to watch it first to understand how Nuvec® sets the stage for the next frontier in RNA-based therapies.

In this video, Nigel, N4 Pharma CEO, dives into the challenges of treating Inflammatory Bowel Disease (IBD) and why we’re developing an RNA-based therapeutic to address the gaps in current treatments. IBD, which includes Crohn’s disease and ulcerative colitis, causes chronic gut inflammation, leading to painful and debilitating symptoms.

While existing treatments like steroids, immunosuppressants, and TNF inhibitors help manage the disease, they come with serious side effects, require injections, and often fail to provide long-term relief.

Nigel explores why small interfering RNA (siRNA) therapeutics offer a promising solution, but also why oral delivery remains a key challenge.

Stay tuned to learn how our innovative approach could revolutionize IBD treatment by delivering targeted therapy directly to the gut—without injections or systemic side effects.

Next up, in the final episode of our Teach-In Series: N4 101: Unlocking the Science Behind Our Innovation.

Inflammatory Bowel Disease: Prevalence and N4 Pharma’s Approach